Clinical implication and immunological landscape analyses of ANLN in pan‐cancer: A new target for cancer research

BACKGROUND: Anillin is a F‐actin binding protein (ANLN) mainly involved in the process of cytokinesis and known to be dysregulated in diverse cancers. However, the role of ANLN in pan‐cancer prognosis and tumor immunity remains unclear. METHODS: Gene expression profiles of 31 solid tumors were downloaded from The Cancer Genome Atlas (TCGA) database. ANLN mRNA and protein expression were quantified using quantitative real‐time PCR (qRT‐PCR) and immunohistochemistry (IHC). Protein expression of ANLN was further confirmed in Human Protein Atlas (HPA) database. Cox regression and Kaplan–Meier analysis were utilized to assess the prognostic value of ANLN in pan‐cancer. The correlation between ANLN and different immune gene markers and infiltration cells was analyzed via ESTIMATE and CIBERSORT. A BLCA immunotherapy cohort: IMvigor (210) was used to confirm the role of ANLN in immune response. RESULTS: ANLN upregulation was detected in 21 types of cancers and was associated with poor overall survival (OS), disease‐free interval (DFI), and progression‐free interval (PFI) in most cancers except in THYM (Thymoma). Additionally, correlation analysis revealed a significantly positive association between ANLN expression and tumor mutation burden (TMB), microsatellite instability (MSI), immune cells infiltration. and immune checkpoint genes in various cancers. The BLCA immunotherapy cohort confirmed that patients with higher ANLN level had better immune responses and longer OS. CONCLUSION: ANLN may serve as a prognostic biomarker for pan‐cancer. ANLN upregulation is associated with higher TMB, MSI, and immune cell infiltration in multiple types of tumors, shedding new light for cancer treatment.